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Abstract
Introduction About a decade ago, synthetic cannabinoids
(SC) started to appear as recreational drugs on the new psy-
choactive substance (NPS) market. This report from the
STRIDA project describes analytically confirmed intoxica-
tions involving MDMB-CHMICA (methyl-2-(1-(cyclohexyl
methyl)-1H-indol-3-ylcarbonylamino)-3,3-dimethylbuta
noate), a SC that was first detected in 2014.
Study Design This is an observational case series of patients
from Sweden with suspected NPS exposure presenting in
emergency departments and intensive care units. The results
of retrospective serum and urine toxicological analysis were
compared with clinical signs reported during consultation
with the Poisons Information Centre and retrieved from med-
ical records.
Methods Clinical and bioanalytical data in nine acute intoxi-
cations associated with MDMB-CHMICA during 2014–2015
are presented. The patients were aged 23–62 (median
34) years, and eight were men. MDMB-CHMICA (parent
compound) was analytically confirmed in serum samples,
using a liquid chromatography–high-resolution mass spec-
trometry multi-component method.
Results Of the nine MDMB-CHMICA-positive patients,
eight had a Poisoning Severity Score (PSS) of 2 or 3, and five
were monitored in the intensive care unit and all patients
survived. Development of seizures and deep unconsciousness
were common features. All cases except one also tested pos-
itive for other NPS and/or classical psychoactive compounds,
hampering the possibility to establish a causal relationship
between drug and toxic symptoms. MDMB-CHMICA was
also identified in seven drug materials donated by the patients.
Conclusions The association with severe adverse reactions in
nine acute analytically confirmed intoxication cases involving
MDMB-CHMICA is consistent with other reports of serious
toxicity linked to this substance, suggesting that MDMB-
CHMICA might be a particularly harmful SC.
Keywords Drug exposure . New psychoactive substances .
Spice . Synthetic cannabinoid receptor agonists . Synthetic
cannabinoids
Introduction
About a decade ago, synthetic cannabinoid receptor agonists
(synthetic Bcannabinoids,^ SC) started to appear as recreation-
al drugs in the form of laced herbal smoking blends. These
substances, of which many were originally developed as drug
candidates and pharmacological probes, are nowadays collec-
tively referred to as Bspice,^ from the brand name of an early
herbal smoking blend. The SC are typically made available
through the rapidly expanding online-sale market for new
psychoactive substances (NPS) [1–3]. Attempts to control
the open sale of yet unclassified SC and other NPS through
substance-specific or generic regulations have led to market
adaptations and the appearance of hundreds of novel chemical
substances since 2008 [4–6].
The SC are functionally similar to Δ9-tetrahydrocannabi-
nol (THC), the principal psychoactive constituent in cannabis,
targeting the main central nervous system receptor (CB1) in
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the endocannabinoid system [7]. Compared with THC, which
is a partial CB1 receptor agonist, many novel SC show full
receptor agonist effect and also a significantly greater affinity,
making themmuch more potent and potentially more toxic [8,
9]. CB receptor overstimulation is therefore a likely cause for
serious adverse events related to SC use [10, 11]. However,
adverse side effects unrelated to the intended psychoactive
targets are an inherent risk with untested NPS and may also
be important in cases of SC toxicity [12].
Since 2014, cases of severe SC toxicity have been re-
ported with increasing frequency in many parts of the
world. During the fall of 2014, SC were involved in at
least 15 deaths and 600 patients requiring medical treat-
ment in Russia [13]. During the same time, concerns
about increases in SC-related harms were also raised in
Sweden. In October and November 2014, the number of
calls related to SC toxicity to the Swedish Poisons
Information Centre equaled the total number of SC-
related calls in 2013 (∼250 calls), and most days com-
prised 5 %, and occasionally even 10 %, of all calls from
hospitals (Fig. 1). Similarly, in the USA, the number of
poison center calls related to SC use more than tripled
during the spring of 2015 with 15 deaths and more than
300 potentially life-threatening cases [14].
The seemingly increasing risk of harm related to SC use is
likely due to a greater toxicity of the novel variants [14], many
of which showing more complex molecular structures com-
pared with THC and the Bfirst generation^ SC (e.g., JWH-018)
(Fig. 2). The Russian cases of severe SC toxicity in 2014 were
suspected to involve MDMB-FUBINACA (also known as
MDMB N-Bz F), whereas ADB-CHMINACA, AB-
CHMINACA, and AB-FUBINACA have been associated
with the US cases [13, 15–19]. MDMB-CHMICA is another
structurally similar SC (Fig. 2) that has attracted growing
attention, since it was first reported to the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) and Europol in the fall of 2014, due to the con-
nection with cases of severe toxicity and fatalities [20–25].
This case series from the STRIDA project presents
clinical and bioanalytical data in nine non-fatal acute in-
toxications analytically confirmed to involve MDMB-
CHMICA (methyl-2-(1-(cyclohexylmethyl)-1H-indol-3-
ylcarbonylamino)-3,3-dimethylbutanoate), one of several




The STRIDA (an acronym in Swedish) project is an ongoing
collaboration since 2010 between the Swedish Poisons
Information Centre and the Karolinska University
Laboratory (Stockholm), aiming to monitor the occurrence
and health hazards of NPS in Sweden. When clinicians con-
tact the Poisons Information Centre (a nationwide 24/7 service
to hospital caregivers and the public) for treatment advice in
acute intoxication cases with suspected exposure to NPS pre-
senting in emergency departments (ED) and intensive care
units (ICU), they are also encouraged to sample blood and
urine for free analysis of psychoactive drug contents [26,
27]. The samples are analyzed for a large number of NPS
and classical drugs-of-abuse (currently >300 substances are
covered). Data on clinical features are collected by the
Poisons Information Centre during consultations and
reviewed retrospectively from medical records. In each case,
the severity of intoxication was graded retrospectively using
Fig. 1 Monthly statistics from
the Swedish Poisons Information
Centre of cases (telephone calls
mainly from hospital caregivers,
but also the public) regarding
suspected intoxications by
synthetic cannabinoids
(SC,Bspice^). Times for Swedish
classification of SC as being
"hazardous to health" are also
indicated
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the Poisoning Severity Score (PSS) [28]. The level of con-
sciousness was defined by the Reaction Level Scale (RLS)
or the Glasgow Coma Scale (GCS) [29, 30].
At the time of the Swedish Bspice epidemic^ in the fall
of 2014, reference material for analytical confirmation of
MDMB-CHMICA was initially missing. Thus, the present
cases of confirmed MDMB-CHMICA exposure were se-
lected from the pool of samples from STRIDA patients
(882 patients from October 2014 to October 2015) and
analyzed retrospectively, because there was a reason to
suspect MDMB-CHMICA poisoning (e.g., the substance
had been mentioned in connection with the intoxication or
the patient brought packets labeled with and/or analytical-
ly confirmed to consist of MDMB-CHMICA).
The STRIDA project is conducted in accordance with
the Helsinki Declaration and is approved by the regional
ethical review board (No. 2013/116–31/2).
Laboratory Analysis
Laboratory investigations of urine specimens for contents of
NPS and classical psychoactive substances were done accord-
ing to published procedures, using both immunochemical
screening assays and multicomponent methods based on liq-
uid chromatography combined with tandem (LC–MS/MS) or
high-resolution (LC–HRMS) mass spectrometry [27, 31, 32].
The analysis of SC including MDMB-CHMICA was per-
formed in serum (parent compounds only) using LC–
HRMS, after a solvent protein precipitation procedure.
Specimens were stored at −20 °C until taken for analysis.
Reference materials for SC, including the novel sub-
stances shown in Fig. 2 (except MDMB-FUBINACA,
for which an early warning system formal notification
on its first detection in Europe was issued in January
2016), were obtained from Chiron AS (Trondheim,
Norway) and Cayman Chemical Co (Ann Arbor, MI,
USA). The limit of detection (LOD) for MDMB-
CHMICA was 0.6 ng/mL and the lower limit of quantifi-
cation (LLOQ) was 1.25 ng/mL.
Drug materials (e.g., powder, tablets, and herbal
smoking mixtures) brought to hospital by the patients
were sometimes sent to the laboratory together with the
serum and urine samples. These items were forwarded to
the Swedish Medical Product Agency (Uppsala) for ana-
lytical investigation, using LC–quadrupole-time-of-flight–
MS/MS (LC–QTOF–MS/MS) and nuclear magnetic reso-
nance (NMR) spectroscopy [33].
Results
Clinical Data and Laboratory Investigations
Data on patient demographics, clinical features, and
bioanalytical results in the nine selected intoxication cases
involving MDMB-CHMICA are presented in Tables 1 and
2. The patients were aged 23–62 (median 34, mean
38.6) years, and all but one were males. With the exception
of cases #1 and #2 (Table 1), of which case #1 is described in
more detail below, all cases were seemingly unrelated and
originated from different parts of Sweden.
Fig. 2 Chemical structures of
synthetic cannabinoids (Bspice^)
recently associated with severe







CHMICA (Europe; present study)
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In eight of the nine cases, both serum and urine specimens
sampled at the same time within 2.5 h after arrival to hospital
were available for analysis. MDMB-CHMICA (parent com-
pound) could not be identified in any urine sample. However,
the serum samples from eight patients contained MDMB-
CHMICA in the range 3.4–86.4 (median 18.6, mean
24.5) ng/mL, whereas the concentration was below the
LLOQ in one case (Table 1). The patient showing by far the
highest substance concentration (86 ng/mL), being twofold
higher than the second highest level, reported previous expe-
rience of smoking Bspice,^ but had smoked for the first times a
new SC named BMMB-CHMINACA^ (an incorrect name for
MDMB-CHMICA often used by internet vendors and in drug
discussion forums) every ∼4 h starting ∼18 h before arrival to
hospital.
All nine cases also tested positive for other NPS and/or
classical drugs of abuse (Table 1), although some of these
substances may have been treatment related. Accordingly,
case #1 was considered to be an MDMB-CHMICA mono-
intoxication, because diazepam which had been given during
acute treatment was the only other substance detected. In ad-
dition to MDMB-CHMICA, four other SC (5F-APINACA,
AMB-FUBINACA, NM-2201, and THJ-018) were identified
in the serum samples (Table 1).
Besides the serum and urine samples, four patients had
brought to hospital a total of seven drug materials that were
also forwarded to the laboratory and later confirmed by LC–
QTOF–MS/MS and NMR to contain MDMB-CHMICA
(Table 3). Two of the materials were unlabeled, two were
labeled BMMB-CHMINACA^ (i.e., MDMB-CHMICA),
whereas three had labels that referred to other SC.
In six drug items, MDMB-CHMICA constituted the only
































































































































































































































































































































































































































































































































































































































































Table 2 Clinical features documented on admission to hospital and/or
collected during telephone consultation with the Swedish Poisons
Information Centre in nine analytically confirmed intoxications involving
MDMB-CHMICA
Clinical features n = 9




Deep unconsciousnessa (RLS ≥5; GCS ≤4) 5
Respiratory depression (RR ≤10/min, SaO2 ≤ 90 %) 5




aMay be influenced by co-exposure of sedatives, postictal state, etc
RLS the Reaction Level Scale [30], GCS Glasgow Coma Scale, RR re-
spiratory rate, SaO2 oxygen saturation, B blood, P plasma
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powders and two were herbal smoking mixtures (Table 3).
Although quantitative 1H-qNMR was not performed, the
NMR data suggested high purity of MDMB-CHMICA in all
powders (≥95 %) and no excipients were detected (personal
communication, K-H Jönsson, Swedish Medical Product
Agency). In addition to MDMB-CHIMCA, traces of other
SC (not verified by NMR) were found in five products
(THJ-018, 5F-PB-22, AMB-FUBINACA, BB-22, and
1-(cyclohexylmethyl)-1H-indole-3-carbonyl)valine). There
was one additional dried herbal product that contained
MDMB-CHMICA belonging to a patient that tested negative
to MDMB-CHMICA and therefore excluded from the present
study; however, in this smoking blend, 5F-APINACA was
present in much higher amount than MDMB-CHMICA.
The most relevant clinical signs and symptoms in the nine
patients testing positive for MDMB-CHMICA are listed in
Table 2. Most features, including development of seizures
and deep unconsciousness (Reaction Level Scale [RLS] ≥5;
Glasgow Coma Scale [GCS] ≤4), were indicated to be more
frequent in the patients showing the lowest serum MDMB-
CHMICA concentrations (<10 ng/mL).
All patients were transported to hospital by ambulance, and
police assistance was needed in two cases. Five patients were
treated with diazepam on ambulance arrival, during transport,
and/or in hospital, and three patients needed sedation with
propofol of which two were intubated. Four patients were
monitored in the ED or in a medical observation unit for
<8 h, while the other five required ICU monitoring of which
one (case #5) needed intensive care for 4 days and was not
discharged home until day 6. The resuming patients were all
discharged within 24 h from admission.
Case Series of MDMB-CHMICA Exposure
Three male in-patients (cases #1, #2, and one test-negative
case that was excluded from the present study) at the same
drug addiction treatment center had ingested an unknown sub-
stance claimed to be Bkrokodil^, Bspice^, or Bbath salt^. The
route of drug administration was never clarified. Within a few
minutes after intake, all three started vomiting, lost conscious-
ness, and had tonic-clonic seizures, according to reports from
the treatment center staff. The paramedics in the first arriving
ambulance administered 5 mg diazepam rectally to each pa-
tient, and they were then transported to two different hospitals.
Both ED teams contacted the Poisons Information Centre for
consultation.
Patient #1 was a 34-year-old man with a history of poly-
substance abuse. During transport to hospital, he was still
seizing despite given diazepam, was bleeding from bites to
his tongue, and was deeply unconscious (GCS 4). He received
an additional 30 mg of diazepam intravenously. His airways
were clear and he breathed spontaneously, receiving 15 L/min
oxygen via a face mask. He was febrile (38 °C), tachycardic
(150/min), and the systolic BP was 90–85 mmHg.
Table 3 Results from analysis of NPS products brought to hospital by patients testing positive for MDMB-CHMICA in serum
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(or a structural isomer)
a Content not verified by NMR
LC–QTOF–MS/MS liquid chromatography-quadrupole-time-of-flight–tandem mass spectrometry, NMR nuclear magnetic resonance spectrometry, SC
synthetic cannabinoids
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Upon arrival to the ED, his initial laboratory parameters in
plasma (pH 7.26, pCO2 7.1 kPa [53 mmHg], pO2 8.0 kPa
[60 mmHg], base excess −4.4 mmol/L, standard bicarbonate
21.0 mmol/L, lactate 3.5 mmol/L, potassium 3.3 mmol/L, and
creatinine 100 μmol/L) showed a mild acidosis. Within 1 h of
observation, he woke up and was communicable although not
completely lucid. His vital signs, including the body temper-
ature, had normalized. The patient opposed continued care at
hospital and was discharged back to the treatment center after
an uneventful 8-h observation period.
In the biological samples that were collected 1 h after ED
admission, MDMB-CHMICA and desmethyldiazepam were
detected; the latter is a metabolite of diazepam and its presence
was likely treatment related. In this and the second related
case, serum MDMB-CHMICA concentrations of 3.8 and
3.4 ng/mL, respectively, were found, whereas the substance
was not detectable in the third related case (hemolytic serum
sample). The sample from the second case also contained
other psychoactive substances (Table 1).
Discussion
The nine selected poisonings involving MDMB-CHMICA
presented in this case series indicate that the novel SC can
cause serious acute harm, thereby being in sharp contrast to
what is typical for cannabis (THC). In this respect, the case
presented in greater detail (case #1) was especially decisive,
because no other substances were detected, and life-
threatening symptoms developed within minutes of drug in-
take. It should be pointed out that MDMB-CHMICA is only
one of several potent SC associated with an outbreak of SC
toxicity (called a Bspice epidemic^ in the media) in Sweden
during the fall of 2014. It is also interesting to note that six of
the nine intoxications involving MDMB-CHMICA occurred,
after the substance had been regulated in Sweden in January
2015 as being Bhazardous to health^ [34].
According to the information from the EMCDDA and
Europol, the first European early warning report on
MDMB-CHMICA originated from Hungary in August
2014. A discussion thread devoted to the substance on a
Swedish internet forum, albeit then incorrectly named
BMMB-CHMINACA,^ was started in mid-September
2014. The first seizure of MDMB-CHMICA by the
Swedish Police occurred in October the same year, as
did the first analytically confirmed poisoning in the
STRIDA project. During the fall of 2014, the substance
was detected in nine autopsy cases in Sweden and in at
least two of those considered as the cause of death [23,
35]. During 2014–2015, MDMB-CHMICA has also been
linked to deaths in Norway [25] and to deaths and cases
of serious toxicity in Germany, Poland, and the UK [20,
21, 24, 36].
The adverse effects noted in the present case series are
consistent with findings from other cases of MDMB-
CHMICA intoxication [21, 24, 36, 37] and with those report-
ed in poisonings involving other potent novel SC [15–19, 38].
Seizures, deep unconsciousness, and agitated delirium were
common clinical findings, all being potentially life-threaten-
ing. A common laboratory finding was the occurrence of a
raised plasma creatinine concentration (≥100 μmol/L).
However, the elevations occurred early in the clinical course
and were relatively mild, suggesting dehydration, muscular
exertion, and possibly rhabdomyolysis, rather than nephrotox-
icity, as the cause.
Besides their high potency (i.e., receptor affinity), the se-
vere toxicity associated with novel SC may in part be related
to the new practice of selling products as pure powders, which
increases the risk of overdose, instead of as ready-for-use herbal
smoking mixtures. The MDMB-CHMICA powder samples
analyzed in this study were demonstrated to be of high purity,
being consistent with discussions on drug forums that they are
intended for making Bstock solutions^ [39].
A somewhat remarkable observation was that the patients
showing a relatively low MDMB-CHMICA concentration in
blood were indicated to display a more severe toxidrome,
compared to the patients with the highest substance levels.
Also in previous studies, however, extremely low concentra-
tions have been reported in fatal cases and severely ill patients
[20, 21, 23, 25, 40]. Contrary, on admission to hospital, one of
the patients (case #7) in the present case series had a relatively
high MDMB-CHMICA concentration in serum (86 ng/mL),
which is about eightfold higher than in previous publications
on related fatalities. This patient admitted recurrent smoking
over the previous ∼18 h, which might have resulted in drug
accumulation and could explain the high level reached. The
patient had developed seizure-like symptoms a few minutes
after the last smoking session, and the blood sample was esti-
mated to have been collected about 1 h after the onset of
symptoms. A similarly high serum MDMB-CHMICA con-
centration, in a subject not displaying any toxicity symptoms,
has been reported once before [21]. This may result from
tolerance building after chronic use of SC [10, 21, 41]. Posts
at discussions online also indicate that frequent use of
MDMB-CHMICA quickly leads to tolerance, since some
users stated smoking 2 g/day within a few weeks, and even
withdrawal symptoms are described [42].
Similar to THC, the SC are lipophilic compounds that are
extensively metabolized, but knowledge about metabolic pat-
terns is often limited, and so is the availability of reference
materials. A common analytical strategy to confirm SC use is
therefore measurement of the parent compounds in blood
specimens, rather than of urinary metabolites which are the
standard procedure for THC (i.e., testing for THC-COOH).
Nevertheless, due to a generally shorter detection window in
blood after drug intake, blood samples need to be collected
58 J. Med. Toxicol. (2017) 13:52–60
closer to exposure [43, 44], and, due to the high potency of
novel SC and hence low substance concentrations, may re-
quire highly sensitive analytical methods [20, 21, 25, 40]. In
some SC studies involving investigation of metabolites, their
presence has mainly been used as additional (confirmatory)
support of drug exposure [16, 19, 37, 45].
The present cases represent only a small part of the Poisons
Information Centre calls on SC presented in Fig. 1. The sub-
stances involved in the Bspice epidemic^ in Sweden at the end
of 2014 are still under investigation, and since then, other
potent and potentially toxic SC have been introduced on the
recreational drugs market. However, it should also be pointed
out that after the peak of harmful cases in the end of 2014, the
number of contacts to the Poisons Information Centre related
to SC has shown a steady decline.
As demonstrated in Fig. 2, MDMB-CHMICA and the oth-
er SC are structurally similar to the substances described in a
2009 Pfizer patent comprising over 700 indazole derivatives
showing CB1 activity [46]. MDMB-CHMICA is the indole
variant of the patented substance MDMB-CHMINACA
which has a CB1 receptor affinity ∼400 times that of THC
[13]. The high toxicity associated with MDMB-CHMICA
use illustrates that the indazole core structure of the Pfizer
patent can be substituted for an indole, without apparent loss
of effect and it is probable that it could also be substituted for
yet other building blocks, e.g., benzimidazole. Thus, the
Pfizer patent could form the basis for a staggering number of
SC for the NPS market [4].
Limitations of this study include missing or unreliable in-
formation about the amount of drug taken, the route of admin-
istration, and the time passing between intake and arrival in
hospital and sampling of blood, as well as the small number of
cases. Also, unknown compound stability and inter-individual
variability in drug metabolism are confounding factors for
MDMB-CHMICA identification. In addition, as in previous
case series on NPS from the STRIDA project, poly-drug use
was found to be common, implying possible risks for interfer-
ences by other psychoactive substances and making it difficult
to link substance concentration levels to severity grade as well
as confirming what clinical signs are specifically related to
MDMB-CHMICA. Finally, because the way clinical informa-
tion is collected is not standardized between hospitals, infor-
mation on less obvious signs and symptoms may have been
missed.
Conclusions
The association with severe adverse reactions in nine acute
analytically confirmed poisonings cases involving MDMB-
CHMICA in Sweden in 2014–2015 is consistent with other
reports of serious toxicity linked to this substance, supporting
that MDMB-CHMICA is one of the more toxic SC found so
far on the NPS market.
Compliance with Ethical Standards The STRIDA project is conduct-
ed in accordance with the Helsinki Declaration and is approved by the
regional ethical review board (No. 2013/116–31/2).
Conflicts of Interest None.
Sources of Funding None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. EMCDDA. EU drug markets report 2016—in-depth analysis.
2016. Available at: http://www.emcdda.europa.eu/system/files/
publications/2373/TD0216072ENN.PDF.
2. Fattore L, Fratta W. Beyond THC: the new generation of cannabi-
noid designer drugs. Front Behav Neurosci. 2011;5:60.
3. Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more
than harmless herbal blends: a review of the pharmacology and
t o x i c o l o g y o f s y n t h e t i c c a n n a b i n o i d s . P r o g
Neuropsychopharmacol Biol Psychiatry. 2012;39:234–43.
4. Advisory Council on the Misuse of Drugs. ‘Third generation’ syn-
thetic cannabinoids. 2014. Available at: https://www.gov.
uk/government/uploads/system/uploads/attachment_data/file/
380161/CannabinoidsReport.pdf.
5. Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of first and
second generation legal highs for synthetic cannabinoids and syn-
thetic stimulants by ultra-performance liquid chromatography and
time of flight mass spectrometry. J Anal Toxicol. 2012;36:360–71.
6. Kikura-Hanajiri R, Kawamura NU, Goda Y. Changes in the preva-
lence of new psychoactive substances before and after the introduc-
tion of the generic scheduling of synthetic cannabinoids in Japan.
Drug Test Anal. 2014;6:832–9.
7. Wiley JL, Marusich JA, Huffman JW. Moving around the mole-
cule: relationship between chemical structure and in vivo activity of
synthetic cannabinoids. Life Sci. 2014;97:55–63.
8. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL.
Distinct pharmacology and metabolism of K2 synthetic cannabi-
noids compared to Delta(9)-THC: mechanism underlying greater
toxicity? Life Sci. 2014;97:45–54.
9. Gurney SM, Scott KS, Kacinko SL, Presley BC, Logan BK.
Pharmacology, toxicology, and adverse effects of synthetic canna-
binoid drugs. Forensic Sci Rev. 2014;26:53–78.
10. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard
S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmaco-
dynamics, and clinical implications. Drug Alcohol Depend.
2014;144C:12–41.
11. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic
review of adverse events arising from the use of synthetic cannabi-
noids and their associated treatment. Clin Toxicol (Phila). 2016;54:
1–13.
J. Med. Toxicol. (2017) 13:52–60 59
12. Centers for Disease Control and Prevention (CDC). Acute kidney
injury associated with synthetic cannabinoid use—multiple states,
2012. MMWR Morb Mortal Wkly Rep. 2013;62:93–8.
13. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y,
Morzherin Y, et al. Identification and analytical characteristics of
synthetic cannabinoids with an indazole-3-carboxamide structure
bearing a N-1-methoxycarbonylalkyl group. Anal Bioanal Chem.
2015;407:6301–15.
14. Law R, Schier J, Martin C, Chang A, Wolkin A. Notes from the
field: increase in reported adverse health effects related to synthetic
Cannabinoid use—United States, January–May 2015. MMWR
Morb Mortal Wkly Rep. 2015;64:618–9.
15. Centers for Disease Control and Prevention (CDC). Notes from the
field: severe illness associated with synthetic cannabinoid use—
Brunswick, Georgia, 2013. MMWR Morb Mortal Wkly Rep.
2013;62:939.
16. Schwartz MD, Trecki J, Edison LA, Steck AR, Arnold JK, Gerona
RR. A common source outbreak of severe delirium associated with
exposure to the novel synthetic cannabinoid ADB-PINACA. J
Emerg Med. 2015;48:573–80.
17. Shanks KG, ClarkW, Behonick G. Death associated with the use of
the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol.
2016;40:236–9.
18. Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related
illnesses and deaths. N Engl J Med. 2015;373:103–7.
19. Tyndall JA, Gerona R, De Portu G, Trecki J, Elie MC, Lucas J, et al.
An outbreak of acute delirium from exposure to the synthetic can-
nabinoid AB-CHMINACA. Clin Toxicol (Phila). 2015;53:950–6.
20. Adamowicz P. Fatal intoxication with synthetic cannabinoid
MDMB-CHMICA. Forensic Sci Int. 2016;261:e5–10.
21. Angerer V, Franz F, Schwarze B, Moosmann B, Auwarter V. Reply
to ‘sudden cardiac death following use of the synthetic cannabinoid
MDMB-CHMICA’. J Anal Toxicol. 2016;40:240–2.
22. EMCDDA. European drug report 2016: trends and developments.
2016. Available at: http://www.emcdda.europa.eu/system/
files/publications/2637/TDAT16001ENN.pdf.
23. Kronstrand R, Tyrkko E, Lindstedt M, Roman M, editors. MMB-
CHMINACA blood concentrations in recreational users and fatal
intoxications. Poster presentation at 53rd The International
Association of Forensic Toxicologists meeting 2015; 2015 August
30th to September 4th; Firenze.
24. Seywright A, Torrance HJ, Wylie FM, McKeown DA, Lowe DJ,
Stevenson R. Analysis and clinical findings of cases positive for the
novel synthetic cannabinoid receptor agonist MDMB-CHMICA.
Clin Toxicol (Phila) 2016:1–6.
25. Westin AA, Frost J, BredeWR, Gundersen PO, Einvik S, Aarset H,
et al. Sudden cardiac death following use of the synthetic cannabi-
noid MDMB-CHMICA. J Anal Toxicol. 2016;40:86–7.
26. Helander A, Beck O, Hägerkvist R, Hultén P. Identification of novel
psychoactive drug use in Sweden based on laboratory analysis—
initial experiences from the STRIDA project. Scand J Clin Lab
Invest. 2013;73:400–6.
27. Helander A, Bäckberg M, Hultén P, Al-Saffar Y, Beck O. Detection
of new psychoactive substance use among emergency room pa-
tients: results from the Swedish STRIDA project. Forensic Sci Int.
2014;243C:23–9.
28. Persson HE, Sjöberg GK, Haines JA, Pronczuk de Garbino J.
Poisoning severity score. Grading of acute poisoning. J Toxicol
Clin Toxicol. 1998;36:205–13.
29. Starmark JE, Stålhammar D, Holmgren E. The reaction level scale
(RLS85). Manual and guidelines. Acta Neurochir (Wien). 1988;91:
12–20.
30. Starmark JE, Stålhammar D, Holmgren E, Rosander B. A compar-
ison of the Glasgow coma scale and the reaction level scale
(RLS85). J Neurosurg. 1988;69:699–706.
31. Al-Saffar Y, Stephanson NN, Beck O. Multicomponent LC-MS/
MS screening method for detection of new psychoactive drugs,
legal highs, in urine-experience from the Swedish population. J
Chromatogr B Analyt Technol Biomed Life Sci. 2013;930:112–20.
32. Bäckberg M, Lindeman E, Beck O, Helander A. Characteristics of
analytically confirmed 3-MMC-related intoxications from the
Swedish STRIDA project. Clin Toxicol (Phila). 2015;53:46–53.
33. Johansson M, Fransson D, Rundlöf T, Huynh NH, Arvidsson T. A
general analytical platform and strategy in search for illegal drugs. J
Pharm Biomed Anal. 2014;100:215–29.
34. Förordning om ändring i förordningen (1999:58) om förbud mot
vissa hälsofarliga varor [Regulation of changing the regulation of
certain goods hazardous to health]. 2014. Available at: http://www.
notisum.se/rnp/sls/sfs/20141481.pdf.
35. EMCDDA. EMCDDA–Europol Joint Report on a new psychoac-
tive substance: methyl 2-[[1-(cyclohexylmethyl)indole-3-
carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA).
2016. Available at: http://www.emcdda.europa.eu/system/files/
publications/2873/2016.4528_WEB.pdf.
36. Hill SL, Najafi J, DunnM, Acheampong P, Kamour A, Grundlingh
J, et al. Clinical toxicity following analytically confirmed use of the
synthetic cannabinoid receptor agonistMDMB-CHMICA. A report
from the Identification Of Novel psychoActive substances (IONA)
study. Clin Toxicol (Phila) 2016;54:638–43.
37. Hermanns-Clausen M, Müller D, Kithinji J, Angerer V, Franz F,
Eyer F, et al., editors. Abstract 17; Acute side effects after consump-
tion of the novel synthetic cannabinoids AB-CHMINACA and
MDMB-CHMICA. 36th International Congress of the European
Association of Poisons Centres and Clinical Toxicologists
(EAPCCT), Madrid, Spain, 2016. Clinical Toxicology, 54:4, 344–
519, DOI: 103109/1556365020161165952; 2016.
38. Adamowicz P, Gieron J. Acute intoxication of four individuals fol-
lowing use of the synthetic cannabinoid MAB-CHMINACA. Clin
Toxicol (Phila) 2016;54:650–4.
39. Flashback. Available at: https://www.flashback.org. Accessed
May 2016.
40. Abouchedid R, Thurtle N, Yamamoto T, J. H, Bailey G, Hudson S,
et al., editors. Abstract 238; Analytical confirmation of the synthetic
cannabinoid receptor agonists (SCRAs) present in a cohort of pre-
sentations with acute recreational drug toxicity to an Emergency
Department (ED) in London, UK. 36th International Congress of
the European Association of Poisons Centres and Clinical
Toxicologists (EAPCCT), Madrid, Spain, 2016. Clinical
Toxicology, 54:4, 344–519, DOI: 103109/1556365020161165952.
41. Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute
toxicity due to the confirmed consumption of synthetic cannabi-
noids: clinical and laboratory findings. Addiction. 2013;108:
534–44.
42. Drugs-Forum–MDMB-CHMICA. Available at: https://drugs-
forum.com/forum/showthread.php?t=253270. Accessed
May 2016.
43. Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M.
Comprehensive review of the detection methods for synthetic can-
nabinoids and cathinones. Forensic Toxicol. 2015;33:175–94.
44. Vikingsson S, Green H. Putting designer drugs back in Pandora’s
box: analytical challenges andmetabolite identification. Clin Chem.
2016;62:4–5.
45. Hermanns-Clausen M, Kithinji J, Spehl M, Angerer V, Franz F,
Eyer F, et al. Adverse effects after the use of JWH-210—a case
series from the EU Spice II plus project. Drug Test Anal 2016.





60 J. Med. Toxicol. (2017) 13:52–60
